WELLINGTON MANAGEMENT GROUP LLP

Position in SYRE — Spyre Therapeutics, Inc.

CIK 902219 Boston, MA

Position in SYRE

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$92,043,462

+$41,288,921 QoQ

Shares Held

1,824,811

+17.8% QoQ

Ownership

2.10%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 0% Shared 69% None 31%

Healthcare · as of Mar 31, 2026

WELLINGTON MANAGEMENT GROUP LLP holds $14,419,413,768 across 180 Biotechnology names. SYRE ranks #38 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,212,589	$1,434,549,489
2	REGN	Regeneron Pharmaceuticals, Inc.	1,837,459	$1,419,694,318
3	ARGX	Argenx SE	1,021,457	$745,918,971
4	ALNY	Alnylam Pharmaceuticals, Inc.	1,935,925	$640,539,501
5	RVMD	Revolution Medicines, Inc.	6,027,819	$586,205,394
6	CYTK	Cytokinetics Inc	8,009,489	$527,905,416
7	IONS	Ionis Pharmaceuticals Inc	6,391,816	$479,961,458
8	ASND	Ascendis Pharma A/S	1,757,633	$402,023,391

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$92,043,462	1,824,811	+17.8%	Shares	Defined	2026-05-15
2025-12-31	$50,754,541	1,549,284	-5.5%	Shares	Defined	2026-02-17
2025-09-30	$27,491,626	1,640,312	+8.4%	Shares	Defined	2025-11-14
2025-06-30	$22,656,763	1,513,478	-5.0%	Shares	Defined	2025-08-14
2025-03-31	$25,713,993	1,593,678	-0.7%	Shares	Defined	2025-05-13
2024-12-31	$37,352,945	1,604,508	+6.5%	Shares	Defined	2025-02-12
2024-09-30	$44,326,750	1,507,200	+89.4%	Shares	Defined	2024-11-14
2024-06-30	$18,712,687	795,946	-2.1%	Shares	Defined	2024-08-14
2024-03-31	$30,831,779	812,860	+27.9%	Shares	Defined	2024-05-15
2023-12-31	$13,674,989	635,455	+111.9%	Shares	Defined	2024-02-12
2023-09-30	$3,674,129	299,929	—	Shares	Defined	2023-12-01
No filing history on record for this holder in this stock.